Affimed Reports Financial Results for Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Affimed Reports Financial Results for Third Quarter 2014

HEIDELBERG, Germany, Nov. 18, 2014 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended September 30, 2014.

"Through the completion of our IPO and additional capital raised this past quarter, Affimed is well-positioned to achieve major value creation milestones for our clinical programs AFM13 and AFM11, as well as to complete preclinical development for AFM21, " said Dr. Adi Hoess, CEO of Affimed. "Affimed remains on target to provide an update on clinical data for both AFM13 and AFM11 during 2015. However, due to a slightly prolonged administrative process, the commencement of the AFM13 phase 2a study is expected to begin in early 2015."

Dr. Hoess added: "In the third quarter, we welcomed the addition of Berndt Modig to our Supervisory Board and look forward to the contribution of his financial experience."

Corporate Highlights

  • Affimed raised a total of €44.3 million (US $56.0 million) before subtracting underwriting discounts and commissions in its initial public offering on the Nasdaq Global Market, which closed on September 17, 2014.
  • Before the IPO, the company announced the closing of a Series E financing from current investors and a loan agreement. The Series E funding totaled €8.2 million ($11 million). The Company has signed a €10.5 million ($14 million) loan agreement with Perceptive Advisors, of which €4.1 million ($5.5 million) has been drawn.
  • The proceeds from the IPO are planned to be used for the continued clinical development of its unencumbered assets AFM13 (indicated for relapsed/refractory patients with Hodgkin Lymphoma and relapsed/refractory patients with Cutaneous T-cell Lymphoma), AFM11 (indicated for relapsed/refractory Non-Hodgkin Lymphoma patients) and AFM21 (targeted for the initiation of IND-enabling studies for the treatment of solid tumors in 2015). In addition, Affimed will enhance its T- and NK-cell platforms, including its proprietary trispecific antibodies for dual targeting of tumors.
  • Affimed expects the dosing of the first patient in the phase 2a clinical study for AFM13 in early 2015, rather than during the fourth quarter of 2014. These updated timelines are the result of an administrative process at the clinical trial sites and are not expected to impact the overall timeline for reporting interim clinical results, which are still anticipated during 2015.
  • Berndt Modig, Chief Financial Officer of Prosensa Holding N.V. (Nasdaq: RNA), has joined the Affimed Supervisory Board and will serve on the company's Audit Committee. Prior to joining Prosensa in 2010, Mr. Modig was CFO at Jerini AG and Surplex AG and held leadership positions at Hayward Industrial Products, the private equity firm Agra Industria and Price Waterhouse.

Financial Highlights

Research and development expenses were €2.2 million for the three months ended September 30, 2014, compared to €2.8 million for the same period in 2013. Net income for the third quarter 2014 was €7.3 million or €2.17 per share, compared to a loss of €11.55 million or €40.36 per share for the third quarter 2013. Net cash used in operating activities was €5.1 million for the nine months ended September 30, 2014 compared to €3.4 million for the nine months ended September 30, 2013. As of September 30, 2014, the company held cash and cash equivalents of €45.5 million. The financial results for the third quarter include certain non-operational and non-monetary effects due to the corporate reorganization in connection with the IPO. Additional information regarding these results is included in the notes to the financial statements as of and for the three and nine month period ending September 30, 2014 and the "Management's Discussion and Analysis of Financial Condition and Results of Operations" which are included in Affimed's Form 6-K as filed with the SEC.

About Affimed N.V.

Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed's prospectus dated September 12, 2014 filed with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Contact:
Affimed N.V.
Adi Hoess, CEO
Phone: +49 6221 65307-0
E-Mail: IR@affimed.com 

AFFIMED N.V. 
 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME/(LOSS)

  For the three months ended September 30 For the nine months ended September 30
  (in € thousand)
  2013 2014 2013 2014
Revenue 191 1,892 462 3,301
Other income/(expenses) - net 109 110 459 223
Research and development expenses (2,790) (2,181) (8,913) (5,468)
General and administrative expenses (3,939) (249) (6,364) (600)
Operating (loss) (6,429) (428) (14,356) (2,544)
Finance income / (costs) - net (5,128) 7,751 (9,202) 7,547
Income / (Loss) before tax (11,557) 7,323 (23,558) 5,003
Income taxes 7 10 9 38
Income / (Loss) for the period (11,550) 7,333 (23,549) 5,041
Total comprehensive income / (loss) (11,550) 7,333 (23,549) 5,041
Earnings / (Loss) per share in € per share (undiluted = diluted) (40.36) 2.17 (82.29) 3.79

AFFIMED N.V.
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

  December 31, 2013 September 30, 2014 (unaudited)
    (in € thousand)
ASSETS    
Non-current assets    
     
Intangible assets 158 96
Leasehold improvements and equipment 1,034 1,044
Deferred tax assets 16 55
  1,208 1,195
Current assets    
     
Inventories 140 187
Trade and other receivables 1,001 932
Cash and cash equivalents 4,151 45,546
  5,292 46,665
     
TOTAL ASSETS 6,500 47,860
     
EQUITY AND LIABILITIES    
Equity    
     
Issued capital 63 240
Capital reserves 469 132,231
Accumulated deficit (99,730) (94,689)
Own shares (25) 0
Total equity (99,223) 37,782
     
Non current liabilities    
     
Preferred shares 77,945 0
Cash settled share based payments 12,838 0
Interest-bearing loans long-term 0 3,670
Total non-current liabilities 90,783 3,670
     
Current liabilities    
     
Derivative conversion feature 6,196 0
Trade and other payables 3,862 4,996
Borrowings 4,800 131
Deferred revenue 82 1,281
Total current liabilities 14,940 6,408
     
TOTAL EQUITY AND LIABILITIES 6,500 47,860

AFFIMED N.V.
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

  For the nine months ended September 30
  2013 2014
  (in € thousand)
Cash flow from operating activities    
Income / (Loss) for the period (23,549) 5,041
Adjustments for the period:    
- Income taxes (9) (38)
- Depreciation and amortisation 308 318
- Non-cash items 6,913 (5,152)
- Finance income / costs - net 9,202 (7,547)
  (7,135) (7,375)
Change in trade and other receivables 143 69
Change in inventories 1 (47)
Change in trade and other payables 3,585 2,333
Cash generated from operating activities (3,406) (5,020)
Interest received 2 0
Paid interest (6) (83)
Net cash used in operating activities (3,410) (5,103)
Cash flow from investing activities    
Purchase of intangible assets (18) (35)
Purchase of leasehold improvements and equipment (128) (242)
Net cash used for investing activities (146) (270)
Cash flow from financing activities    
Proceeds from issue of common shares 0 43,213
Transactions costs related to issue of common shares 0 (4,578)
Proceeds from issue of preferred shares 0 2,999
Proceeds from convertible debt 5,100 0
Transactions costs related to preferred shares and convertible debt (5) 0
Proceeds from Interest-bearing long-term loans 0 4,020
Proceeds from other borrowings 0 130
Cash flow from financing activities 5,095 45,784
     
Net changes to cash and cash equivalents 1,539 40,411
Cash and cash equivalents at the beginning of the period 4,902 4,151
Exchange-rate related changes of cash and cash equivalents 0 984
Cash and cash equivalents at the end of the period 6,441 45,546

AFFIMED N.V.
UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

  Issued capital Capital reserves Own shares Accumulated deficit Total equity
  (in € thousand)
Balance as of January 1, 2013 63 469 (25) (73,631) (73,124)
Income / (Loss) for the period       (23,549) (23,549)
Balance as of September 30, 2013 63 469 (25) (97,180) (96,673)
Balance as of January 1, 2014 63 469 (25) (99,730) (99,223)
Exchange of preferred shares 97 81,909 25   82,031
Issue of common shares 80 41,554   41,634  
Modification of cash-settled share based payment awards   7,648      
Equity-settled share based payment awards   38     38
Issue of warrant note (Perceptive loan)   613     613
Income for the period       5,041 5,041
Balance as of September 30, 2014 240 132,231 0 (94,689) 37,782

HUG#1872391

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 120

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 115

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
Another Nine's A9OS Puts Software at Center of Golf

Updated Category News Views 63

A golf simulator chain is trying to turn the boring plumbing into its sharpest club. Another Nine’s A9OS is not merely a booking widget dressed up for a franchise brochure; it is meant to run the whole 24/7 operation, from payments and door access to cameras, simulator support and guest help. That ambition deserves attention because this is exactly where a staff-free...

Continue Reading
Markley’s Lowell Campus Turns Data Land Into Arboretum

Updated Category News Views 43

Server halls rarely get credited with restoring a landscape, which is why Markley’s Lowell campus caught my eye. On November 18, 2026, the company said its Lowell data center campus had earned Level I arboretum accreditation from the ArbNet Arboretum Accreditation Program. ArbNet describes itself as the only international accreditation program specifically for arboreta,...

Continue Reading
Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 63

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Redseer's $5M Bet on Faster MENA Decision Intelligence

Updated Category News Views 87

Speed has become the expensive commodity in Middle Eastern commerce, and Redseer is putting roughly $5 million behind the idea that executives will pay to get it. Its newly launched Benchmarks MENA 2.0 platform combines proprietary market data with strategic advisory across nine MENA markets. That sounds like another corporate dashboard pitch until you consider the target...

Continue Reading
Yoodli's No. 9 Ranking Signals Enterprise AI Traction

Updated Category News Views 102

Ninth place can be easy to dismiss until you notice the company is sitting near the top of a 500-name growth list. Yoodli's No. 9 position on Deloitte's 2026 Technology Fast 500 is a meaningful signal that its AI-based coaching and workforce-skills pitch is getting traction inside large organizations. It is not a revenue disclosure, it is not a valuation marker, and...

Continue Reading
Paladone Tests LEGO's Everyday Collectibles Pull Abroad

Updated Category News Views 139

A glowing minifigure lamp is not exactly a macroeconomic event, but licensed merchandise has a funny way of revealing where household spending still has a pulse. Paladone Products has put its first LEGO-branded collection into stores, a modest-looking launch with some real retail logic behind it. This is not a grand toy-box bet on one blockbuster item. It is a spread of...

Continue Reading
Schloss Johannisberg Leads 2026 Global Vineyard List

Updated Category News Views 17

A 1,200-year-old riesling estate just beat the world at being memorable. Schloss Johannisberg in Germany’s Rheingau has taken No. 1 in The 50 Best Vineyards 2026, moving up from No. 2 last year and also claiming Best Vineyard in Europe. For anyone watching the wine business from the outside, this is not really a story about one bottle edging out another. It is a...

Continue Reading
24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 121

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading

Top 5 Most Recently Viewed Articles

Nvidia's Strategic Path in AI and Future Possibilities

Updated Category News Views 133

Nvidia's rise as a leader in artificial intelligence was no accident. The tech giant smashed revenue and profit records that had traders buzzing back then. Everyone who jumped on Nvidia over the past couple of years likely scored some serious gains. But here's where it gets tricky: what’s next? Long-term thinking is crucial; it's one thing to ride the wave when...

Continue Reading
Exploring the Rise of AvaTrade and Its User-Friendly App

Updated Category News Views 167

Understanding AvaTrade – A Comprehensive Trading Platform AvaTrade is a highly regarded global trading platform founded to offer access to a variety of financial markets. With licenses from multiple recognized regulatory bodies, the platform ensures high standards of transparency and investor protection, allowing users to engage in trading with confidence. Wide Range of...

Continue Reading
Honka Fusion+: A Breakthrough in Sustainable Wood Construction

Updated Category News Views 192

Honka Fusion+: A Breakthrough in Sustainable Wood Construction Honka, a leader in the realm of modern wood construction, has recently introduced an exciting innovation in the form of Honka Fusion+. This new generation of non-settling CLT (cross-laminated timber) logs is set to revolutionize the construction industry by pushing the boundaries of what can be achieved with...

Continue Reading
Analyzing Recent Trading Trends for Honeywell International

Updated Category News Views 152

Understanding Current Options Trading Dynamics for Honeywell Intl Investors with significant financial resources have recently exhibited a bullish sentiment towards Honeywell International (NASDAQ: HON). This trend is noteworthy and should certainly be on the radar of market participants. Our observations from the public options data highlight this noticeable movement...

Continue Reading
Lineage, Inc. Faces Class Action Lawsuit Over Fraud Allegations

Updated Category News Views 217

Investors Encouraged to Act on Lineage, Inc. Class Action In light of recent developments, investors in Lineage, Inc. are strongly urged to engage with Kirby McInerney LLP regarding a class action lawsuit stemming from alleged securities fraud. This legal action is specifically focused on investors who acquired Lineage securities during a defined period, particularly...

Continue Reading